« Return to News | Ethics/Regulatory | Drug Sponsors

FDA issues warning letter to Sanofi-aventis

Tuesday, March 1, 2011 08:00 AM

The FDA has warned Sanofi-Aventis’ U.S. unit for failing to submit reports of possible serious drug side effects in a timely manner. In a Jan. 28 letter made public last week, the FDA said an early response from the drugmaker and its "promised corrective actions are inadequate to address the deficiencies."

Sanofi spokesman Jack Cox said the company acknowledged the FDA's observations and is working with it to comply. The letter stems from agency inspections of Sanofi's Bridgewater, N.J., facility in April and May 2010, where it found Sanofi had inadequate procedures in place to monitor adverse events and failed to submit serious and unexpected adverse drug experiences by the FDA's deadline.

It also did not include information on postmarketing studies for several drugs—including diabetes drug Apidra, colon cancer drug Eloxatin and antibiotic Ketek—in its annual report to the FDA. Information on completed, unpublished clinical trials of Apidra, Eloxatin and sleep aid Ambien were also not submitted as required.

Sanofi responded to the agency in June, July and October 2010 with plans to correct the problem, but the FDA said its response was lacking. It told Sanofi to take prompt action and respond within 15 days.

Separately, the FDA warned Sanofi's German unit regarding manufacturing violations that led to contamination issues. That letter, dated Feb. 9, cited Sanofi for not having proper written or manufacturing procedures in place or staff properly trained to prevent contamination. Sanofi's Cox said it had moved quickly to address the problems and takes the matter seriously.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.